45 results on '"Choufi, Bachra"'
Search Results
2. Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report
3. Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
4. Naïve subset develops the most important alloreactive response among human CD4+ T lymphocytes in Human Leukocyte Antigen-identical related setting
5. High total metabolic tumor volume at baseline predicts survival independent of response to therapy
6. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin–based reduced-intensity preparative regimen
7. Ibrutinib Treatment through Nasogastric Tube in a Comatose Patient with Central Nervous System Localization of Mantle Cell Lymphoma
8. Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis
9. Autologous hematopoietic stem-cell transplant in small-sized and peripheral centers: a 10-year experiment
10. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy
11. Chemotherapy Treatment Doesn't Beneficiate to a Group of Elderly AML Patients with Absence of Complex Karyotype and Circulating Blasts
12. Impact of Total Metabolic Tumor Volume at Baseline in the Remarc Study
13. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts-de-France AML observatory
14. Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report
15. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
16. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
17. Bendamustine-Based (BeEAM) Conditioning before Autologous Stem Cell Transplantation: Result of a French Multicenter Study of 386 Patients from Lysa Centers
18. Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts‐de‐France AML observatory.
19. Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases
20. Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study
21. Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study
22. Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial
23. Efficacité et innocuité d’une déplétion partielle et sélective des greffons de cellules souches hématopoïétiques : étude de l’alloréactivité, et des réponses antiinfectieuses et anti-tumorales des sous-populations lymphocytaires T4 naïves et mémoires
24. Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)
25. Epidemiology of Adults AML in Nord-Pas De Calais and Picardy
26. Naïve subset develops the most important alloreactive response among human CD4+T lymphocytes in Human Leukocyte Antigen‐identical related setting
27. Maintenance Therapy With Alternating Azacytidine and Lenalidomide Cycles In Elderly (≥ 60) Fit Patients (Pts) With Poor Prognosis AML In First Complete Remission (CR) After Lia Induction. A Phase II Multicentric Goelams Trial
28. Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM
29. Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial
30. The thymus in allogeneic haematopoietic stem cell transplantation
31. Intrinsic Survival Capacity of Cord Blood T cells is heterogeneous and Can Be Promoted by Repeated Low-Doses of Recombinant Interleukin-7,
32. Plasma Levels of Soluble Interleukin-7 Receptor Alpha (sIL-7Ra) and IL-7Ra Polymorphism After Allogeneic Stemcell Transplantation,
33. Naive CD4+ T Cells Exert Superior Alloreactive Capacity Than Central Memory CD4+ T Cells in Fully HLA-Matched Setting
34. Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone
35. Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs)
36. Bortezomib, Doxorubicin and Dexamethasone (PAD) Prior to High-Dose Melphalan / Autologous Stem Cell Transplantation for Newly Diagnosed Plasma Cell Dycrasias.
37. Naïve subset develops the most important alloreactive response among human CD4+ T lymphocytes in Human Leukocyte Antigen-identical related setting.
38. Interphase cytogenetics and competitive RT‐PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon‐α therapy
39. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors
40. Naive CD4+T Cells Exert Superior Alloreactive Capacity Than Central Memory CD4+T Cells in Fully HLA-Matched Setting
41. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
42. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
43. Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
44. [Hematopoietic growth factors and autologous or allogeneic stem cell transplantation].
45. Gene Expression in Human Acute Cutaneous and Hepatic Graft- Versus -Host Disease after Allogeneic Bone Marrow Transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.